Company / Net Income
Revolution Medicines, Inc. Net Income History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$1.1B
FY2025
5-year range
-$1.1B / -$47.7M
FY2021-FY2025
Trend
-88.5%
vs FY2024
Sector context
#211 of 216
Health Care
What the data says
Among 216 Health Care companies, Revolution Medicines, Inc. is in the bottom 2% for net income. Net Income has declined for 5 consecutive years, from -$42M in FY2020 to -$1.1B in FY2025.
Based on SEC 10-K filings.
-$1.1B in FY2025.
Declined from -$436M to -$1.1B over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 2% in Health CareTop 98% of 216This company -$1.1B Sector average $454.1M
▼
-349.1% below sector average
Key checks
Key Insights
- Revolution Medicines, Inc.'s net income has declined for 5 consecutive years.
- In FY2025, net income decreased 88.5% year-over-year.
- Ranks #211 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -1.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.1B | -88.5% |
| FY2024 | -$600.1M | -37.5% |
| FY2023 | -$436.4M | -303.4% |
| FY2022 | -$108.2M | -126.9% |
| FY2021 | -$47.7M | -14.1% |
| FY2020 | -$41.8M | +12.3% |
| FY2019 | -$47.7M | -14.1% |
| FY2018 | -$41.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026